nivolumab,ipilimumab
bms
['lcsm,(-blcsm)', 'nivo', 'nivolumab', 'ipilimumab']
ifct-1701: shorter duration of nivolumab plus ipilimumab in patients with disease control at 6 months by . although closed early, a solid signal could be felt in the results. stay tuned to jcog1701 by dr. yasushi goto. #lcsm #esmo22 
Medical Oncologist, National Cancer Center Hospital, Lung Cancer Study Group @JCOG_official, Educational Committee @JSMO_official, @JLCS_OFFICIAL, @IASLC